Document Detail


Caspase-dependent molecular mechanisms of anti-human DR5 monoclonal antibody mDRA-6 inducing apoptosis of human leukemia Jurkat cells.
MedLine Citation:
PMID:  19550122     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND AND OBJECTIVE: Both tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and some monoclonal agonistic antibodies against TRAIL receptors have antitumor activity. We have previously prepared a novel monoclonal agonistic antibody against human death receptor 5 (DR5) and designated it as mDRA-6. This study was to explore the Caspase-dependent molecular mechanisms of mDRA-6 inducing apoptosis of human leukemia Jurkat cells. METHODS: After exposure to different doses of mDRA-6, DNA fragmentation of Jurkat cells was detected by agarose gel electrophoresis, cell proliferation was detected by MTT assay, and cell apoptosis was detected by flow cytometry after Annexin V-FITC/PI double staining. Jurkat cells were further treated with the inhibitors for Caspase-10, -9, -8 and -3. The active cleavage products of Caspase-10, -9, -8, -3 and poly ADP-ribose polymerase (PARP), BH3 interacting domain death agonist (Bid), truncated Bid (tBid) and cytochrome c (Cyto c), were analyzed by western blot. RESULTS: After mDRA-6 treatment, DNA fragmentation was detected in Jurkat cells. mDRA-6 inhibited cell proliferation in a dose-dependent manner. When treated with 2.0 microg/mL mDRA-6, the apoptosis rates of Jurkat cells were 16.2% at 0.25 h, 28.3% at 0.5 h, 69.2% at 1 h and 78.2% at 2 h. Interestingly, the mDRA-6-induced apoptosis was repressed by 77.9% by Caspase-8 inhibitor ZIF, 54.2% by Caspase-3 inhibitor ZDF, and 8.7% by Caspase-9 inhibitor ZLF, but was not repressed by Caspase-10 inhibitor ZAF. After mDRA-6 exposure, the proenzymes of Caspase-8, -9 and -3 were reduced and their active cleavage products were increased along with the increase of exposure time, the cleavage products of PARP were also increased, Bid was degraded to tBid, and an abundance of Cyto c was released from mitochondria, but the proenzyme of Caspase-10 showed no change and no cleavage products of Caspase-10 were detectable. CONCLUSION: mDRA-6 can induce apoptosis of Jurkat cells via the Caspase-dependent and mitochondrial pathways.
Authors:
Yao-Wu Du; Guang-Chao Liu; Jing Wang; Yue-Ping Zhao; Shu-Lian Li; Ju-Gao Chen; Qi Jiang; Jing Cai; Yuan-Fang Ma
Publication Detail:
Type:  Journal Article     Date:  2009-02-27
Journal Detail:
Title:  Ai zheng = Aizheng = Chinese journal of cancer     Volume:  28     ISSN:  1000-467X     ISO Abbreviation:  Ai Zheng     Publication Date:  2009 Feb 
Date Detail:
Created Date:  2009-06-26     Completed Date:  2009-10-22     Revised Date:  2010-02-04    
Medline Journal Info:
Nlm Unique ID:  9424852     Medline TA:  Ai Zheng     Country:  United States    
Other Details:
Languages:  eng     Pagination:  112-6     Citation Subset:  IM    
Affiliation:
Institute of Immunology, Medical College, Henan University, Kaifeng, Henan, PR China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / pharmacology*
Apoptosis / drug effects*
BH3 Interacting Domain Death Agonist Protein / metabolism
Blotting, Western
Caspase 10 / antagonists & inhibitors,  metabolism
Caspase 3 / antagonists & inhibitors,  metabolism
Caspase 8 / antagonists & inhibitors,  metabolism
Caspase 9 / antagonists & inhibitors,  metabolism
Caspases / antagonists & inhibitors,  metabolism*
Cell Proliferation / drug effects
Cytochromes c / metabolism
DNA Fragmentation / drug effects
Dose-Response Relationship, Drug
Electrophoresis, Agar Gel
Flow Cytometry
Humans
Jurkat Cells
Leukemia / enzymology,  pathology
Oligopeptides / pharmacology
Poly(ADP-ribose) Polymerases / metabolism
Receptors, TNF-Related Apoptosis-Inducing Ligand / immunology*
Time Factors
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/BH3 Interacting Domain Death Agonist Protein; 0/BID protein, human; 0/Oligopeptides; 0/Receptors, TNF-Related Apoptosis-Inducing Ligand; 0/benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone; 0/benzyloxycarbonyl-alanyl-glutamyl-valyl-aspartic acid fluoromethyl ketone; 0/benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone; 0/benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone; 9007-43-6/Cytochromes c; EC 2.4.2.30/Poly(ADP-ribose) Polymerases; EC 3.4.22.-/Caspase 10; EC 3.4.22.-/Caspase 3; EC 3.4.22.-/Caspase 8; EC 3.4.22.-/Caspase 9; EC 3.4.22.-/Caspases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Correlation of Notch1 expression and activation to cisplatin-sensitivity of head and neck squamous c...
Next Document:  Biological characteristics of dendritic cells derived from peripheral blood of patients with epithel...